Elan Drug Technologies has a number of products available for licensing to pharmaceutical companies in the U.S. and worldwide. These products have incorporated one or more of our drug delivery technologies and are at late stage development or approved for marketing. Other products at earlier stage development are also available for licensing.

1. Product Availability List
2011
Non-Confidential Information Pack
DATE: Q1 2011

2. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Elan Drug Technologies’ Product Availability List
Elan Drug Technologies has a number of products available for licensing to pharmaceutical companies in the U.S. and
worldwide. These products have incorporated one or more of our drug delivery technologies and are at late stage
development or approved for marketing. Other products at earlier stage development are also available for licensing.
If you are interested in discussing any of these product opportunities in more detail or wish to obtain more information under
confidentiality or wish to discuss in-licensing opportunities in general, please contact us:
USA Scott Jenkins – Shawn.Bridy@elan.com
ROW Sarah Carty – Sarah.Carty@elan.com
Page 2 of 13
More detailed non-confidential packages are available on request on all products profiled here

3. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Docetaxel Solvent Free Formulation
Taxanes/Solid Tumour cancers.
Class/Indication
Lyphophilised, nanoparticulate IV formulation of
Dosage Form Docetaxel.
Preclinical dose ranging studies performed.
Dosage Strength
Unlike Taxotere®, Elan Drug Technologies' NanoCrystal®
formulation does not require solvents such as
polysorbate 80 and ethanol to solubilise the drug.
The NanoCrystal® formulation contains sterilised water
and GRAS stabilisers and is devoid of solvents.
Comment
Elan Drug Technologies is seeking a licensing partner
that has development and marketing expertise in
oncology to develop and market this unique formulation
of docetaxel.
Clinical development.
Licensing Status
Available for licensing all territories.
Page 3 of 13
More detailed non-confidential packages are available on request on all products profiled here

4. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Twice Daily, novel controlled release hydrocodone for Severe Pain
Opioid for severe pain relief.
Class/indication
Twice daily.
Dosage Frequency
Oral dosage form using the SODAS® technology.
Dosage Form
A novel, oral, single-entity, controlled-release formulation
of hydrocodone, developed using Elan Drug
Technologies’ SODAS® technology, is being studied for
the treatment of moderate to severe chronic pain in
individuals who require around-the-clock opioid therapy
for the control of pain in the US.
Comment
At present there are no products available as single-
entity, controlled-release formulations of hydrocodone in
the United States. Using Elan Drug Technologies’
SODAS® technology, this product, offers a unique,
controlled-release profile which utilises both immediate
release and extended release properties designed to
enable twice daily dosing.
Phase II trials complete, undergoing Phase III studies in
the US.
Licensing Status
Available for licensing in all territories ex-US.
Page 4 of 13
More detailed non-confidential packages are available on request on all products profiled here

5. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Intravenous, Once Daily, Rapid Onset, Non-Opioid for Acute Pain
Management
Non-steroidal anti-inflammatory, pain relief.
Class/indication
Once daily.
Dosage Frequency
Intravenous Formulation using NanoCrystal® technology
Dosage Form
Elan Drug Technologies is seeking a licensing and
development partner for its’ novel NanoCrystal®
formulation of an IV NSAID for use targeting acute pain
relief.
Comment An aqueous IV formulation whose target profile includes
a rapid onset of action and a 24-hour duration of action.
It is stable at ambient temperature and available in a
ready to use vial. No refrigeration or reconstitution is
required prior to administration.
Phase II trials complete.
Licensing Status
Available for licensing in all territories.
Page 5 of 13
More detailed non-confidential packages are available on request on all products profiled here

6. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Megestrol acetate
Progestins/Cachexia.
Class/Indication
5ml.
Dosage Frequency
Oral suspension using the NanoCrystal® technology.
Dosage Form
625mg/5ml.
Dosage Strength
Through applying the NanoCrystal® technology, a
superior more palatable product with a significantly lower
dosage than original product was developed.
Therapeutic Viscosity reduced 16-fold, volume swallowed reduced by
Advantage 75% and has a free of food effect.
Indicated for treatment of anorexia, cachexia or
unexplained significant weight loss in patients with AIDS.
Approved and launched in the US in 2005 as Megace®
ES.
Licensing Status
Available for licensing in all territories ex-US.
Phase III studies complete in Europe.
Page 6 of 13
More detailed non-confidential packages are available on request on all products profiled here

7. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Morphine Once Daily (Avinza®, Morphelan®)
Narcotic analgesic/Severe chronic pain.
Class/indication
Once daily.
Dosage Frequency
Multiparticulate SODAS® beads in hard gelatin capsules.
Dosage Form
30mg, 60mg, 90mg and 120mg.
Dosage Strength
Elan Drug Technologies has received approval with the
FDA and is marketing through a licensing partner in the
U.S. their once daily oral morphine product which gives
round the clock pain relief without breakthrough pain.
Comment Other once daily formulations, which have been
launched, do not provide adequate cover for full 24-hour
relief and often have to be supplemented with other
analgesics to relieve breakthrough pain - this Elan Drug
Technologies formulation overcomes this problem.
Approved and launched in the US in 2002.
Licensing Status Filed in Europe, available for licensing in all territories
ex-North America.
Page 7 of 13
More detailed non-confidential packages are available on request on all products profiled here

8. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Naproxen Sodium (Naprelan®)
Non-steroidal anti-inflammatory/anti-rheumatic, pain
Class/Indication relief.
Once daily.
Dosage Frequency
High-density multiparticulate IPDAS® cores in a
Dosage Form specialised table matrix
500 mg
Dosage Strength
Elan Drug Technologies has developed a once daily
form of Naproxen for use as anti-rheumatic/arthritic and
analgesic.
The specialised tablet matrix allows for rapid
disintegration and a micro-dispersion of the IPDAS®
Comment
cores in the gastrointestinal tract.
The nature of the controlled diffusion and absorption of
Naprelan® reduces gastrointestinal side effects normally
seen with naproxen.
Launched in the US and Canada.
Licensing Status
Available for licensing in all territories ex-North America.
Page 8 of 13
More detailed non-confidential packages are available on request on all products profiled here

9. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Novel Diagnostic Imaging Agents
Diagnostic imaging agents.
Class/Indication
Nanoparticulate size diagnostic agents using
Dosage Form NanoCrystal® formulation
Elan Drug Technologies’ portfolio of novel, NanoCrystal®
diagnostic imaging agents have clear advantages over
current iodinated contrast agents. A portfolio of patent
protected diagnostic agents is available for licensing
which have excellent contrast for an extended period of
time. EDT’s portfolio of NanoCrystal® imaging agents are
Comment
poorly-water soluble, non-osmotic, iodine-rich
compounds. Adjustable hydrolysable linkages allow for a
controlled elimination and slow diffusion of the Nano- DI
agents which provide significantly longer residence time
than current iodinated agents.
EDT has a portfolio of imaging compounds in pre-clinical
development. Lead compounds have been identified,
which have been found to be stable.
Licensing Status
To date, in vivo studies have been completed in rabbits.
Available for licensing in all territories worldwide.
Page 9 of 13
More detailed non-confidential packages are available on request on all products profiled here

10. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Verapamil (Verelan®)
Calcium antagonist/Antihypertensive/antianginal.
Class/Indication
Once daily.
Dosage Frequency
Multiparticulate SODAS® beads in hard gelatin capsules.
Dosage Form
80 mg, 120 mg, 180 mg, 240 mg and 360mg.
Dosage Strength
Verelan® is a unique once daily formulation of
Verapamil.
It is approved for once daily administration up to the
maximum total daily dose, whereas other SR products
Comment are required to be administered in divided doses.
Also, Verelan® does not exhibit any food effects and a
wide range of dosage options are available, allowing for
easy titration for all patients.
Launched in US, Japan and some European and Asian
markets.
Licensing Status
Available for licensing in number of European territories.
Page 10 of 13
More detailed non-confidential packages are available on request on all products profiled here

11. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Verapamil PM (Verelan® PM)
Calcium antagonist/ Antihypertensive/antianginal.
Class/Indication
Dosage Frequency Once daily.
Multiparticulate CODAS® beads in hard gelatin capsules.
Dosage Form
100mg, 200mg and 300mg.
Dosage Strength
Verelan® PM is a unique once daily formulation of
Verapamil which offers the patient maximum protection
against the morning surge in blood pressure when
patients are most at risk.
The CODAS® technology provides peak dose levels in
Comment
the early morning.
Also, Verelan® PM does not exhibit any food effects and
a wide range of dosage options are available, allowing
for easy titration for all patients.
Launched in the US.
Licensing Status
Available for licensing all territories ex-US.
Page 11 of 13
More detailed non-confidential packages are available on request on all products profiled here

12. Product Availability List
Non-Confidential Information Pack | DATE: 2011
Company Profile
Elan Drug Technologies is seeking a marketing partner on an exclusive or territory basis. Elan Drug Technologies will retain
commercial manufacturing rights of these products. Elan believes this directly benefits the potential partner due its expertise
and successful track record in formulation, scale-up and manufacturing.
About Elan Drug Technologies
Elan Drug Technologies is the world’s leading drug delivery company and is a business unit of Elan (NYSE:ELN). As a fully
integrated drug delivery business, we deliver clinically meaningful benefits to patients, by using our extensive experience
and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative
products. For 40 years, we have been applying our skills and knowledge from concept development, right through to full
scale manufacturing. We have been, and continue to be, the drug delivery provider of choice for a broad range of
pharmaceutical companies, including many of the world’s largest pharmaceutical companies. For more information about
Elan’s technology offerings, please visit http://www.elandrugtechnologies.com.
Page 12 of 13
More detailed non-confidential packages are available on request on all products profiled here

13. Contact us
USA ROW
Shawn Bridy Dr Sarah Carty
Director, Business Development Director, Business Development
Elan Drug Technologies Elan Drug Technologies
3500 Horizon Drive Treasury Buildings, Lwr Grand Canal St,
King of Prussia, PA 19406 Dublin 2, Ireland
T 610 270 8442 T +353 1 709 4046
E shawn.bridy@elan.com E sarah.carty@elan.com